1. Home
  2. KRYS vs PRAX Comparison

KRYS vs PRAX Comparison

Compare KRYS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krystal Biotech Inc.

KRYS

Krystal Biotech Inc.

N/A

Current Price

$327.51

Market Cap

9.6B

Sector

Health Care

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$288.69

Market Cap

8.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRYS
PRAX
Founded
2015
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
8.3B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
KRYS
PRAX
Price
$327.51
$288.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
19
Target Price
$392.11
★ $638.68
AVG Volume (30 Days)
204.3K
★ 357.8K
Earning Date
11-02-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 128.00
N/A
EPS
★ 3.62
N/A
Revenue
★ $389,130,000.00
N/A
Revenue This Year
$31.33
N/A
Revenue Next Year
$27.55
$39,590.54
P/E Ratio
$93.08
★ N/A
Revenue Growth
★ 33.94
N/A
52 Week Low
$179.16
$50.31
52 Week High
$382.54
$392.70

Technical Indicators

Market Signals
Indicator
KRYS
PRAX
Relative Strength Index (RSI) 41.98 35.63
Support Level $331.79 $282.35
Resistance Level $371.16 $354.17
Average True Range (ATR) 9.85 14.63
MACD -1.37 -1.65
Stochastic Oscillator 17.44 21.96

Price Performance

Historical Comparison
KRYS
PRAX

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: